West Pharmaceutical Servs Analyst Ratings
West Pharmaceutical Servs Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/30/2023 | 6.69% | Keybanc | $415 → $440 | Maintains | Overweight |
08/21/2023 | 0.63% | Keybanc | $385 → $415 | Maintains | Overweight |
07/28/2023 | -6.65% | Keybanc | $375 → $385 | Maintains | Overweight |
07/17/2023 | 1.84% | Stephens & Co. | $400 → $420 | Maintains | Overweight |
06/16/2023 | -1.8% | B of A Securities | $390 → $405 | Upgrades | Neutral → Buy |
04/11/2023 | -3.01% | Stephens & Co. | $330 → $400 | Upgrades | Equal-Weight → Overweight |
02/17/2023 | -9.07% | Keybanc | $315 → $375 | Maintains | Overweight |
12/14/2022 | -39.38% | Deutsche Bank | → $250 | Initiates Coverage On | → Hold |
12/02/2022 | -23.62% | Keybanc | $350 → $315 | Maintains | Overweight |
11/30/2022 | -39.38% | UBS | → $250 | Initiates Coverage On | → Neutral |
10/28/2022 | -39.38% | B of A Securities | $385 → $250 | Downgrades | Buy → Neutral |
10/28/2022 | -15.13% | Keybanc | $400 → $350 | Maintains | Overweight |
07/29/2022 | -16.35% | Stephens & Co. | $330 → $345 | Maintains | Equal-Weight |
04/29/2022 | -0.58% | B of A Securities | $475 → $410 | Maintains | Buy |
04/29/2022 | -3.01% | Keybanc | $475 → $400 | Maintains | Overweight |
09/15/2021 | 24.88% | B of A Securities | $450 → $515 | Maintains | Buy |
07/30/2021 | -3.01% | Stephens & Co. | $360 → $400 | Maintains | Equal-Weight |
07/30/2021 | 15.18% | Keybanc | $350 → $475 | Maintains | Overweight |
04/30/2021 | -17.56% | Stephens & Co. | $315 → $340 | Maintains | Equal-Weight |
02/19/2021 | -23.62% | Stephens & Co. | $300 → $315 | Maintains | Equal-Weight |
11/10/2020 | -15.13% | Keybanc | → $350 | Initiates Coverage On | → Overweight |
10/14/2020 | -27.26% | Stephens & Co. | → $300 | Initiates Coverage On | → Equal-Weight |
04/24/2020 | — | B of A Securities | Upgrades | Underperform → Neutral | |
12/12/2019 | — | B of A Securities | Downgrades | Neutral → Underperform | |
07/26/2019 | — | B of A Securities | Upgrades | Underperform → Neutral | |
05/01/2019 | — | Jefferies | Downgrades | Buy → Hold | |
04/23/2019 | — | William Blair | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
08/30/2023 | 6.69% | Keybanc | 415 美元 → 440 美元 | 维护 | 超重 |
08/21/2023 | 0.63% | Keybanc | 385 美元 → 415 美元 | 维护 | 超重 |
07/28/2023 | -6.65% | Keybanc | 375 美元 → 385 美元 | 维护 | 超重 |
07/17/2023 | 1.84% | Stephens & Co. | 400 美元 → 420 美元 | 维护 | 超重 |
06/16/2023 | -1.8% | B of A 类证券 | 390 美元 → 405 美元 | 升级 | 中性 → 买入 |
04/11/2023 | -3.01% | Stephens & Co. | 330 美元 → 400 美元 | 升级 | 重量相等 → 超重 |
02/17/2023 | -9.07% | Keybanc | 315 美元 → 375 美元 | 维护 | 超重 |
2022 年 12 月 14 日 | -39.38% | 德意志银行 | → 250 美元 | 启动覆盖开启 | → 按住 |
12/02/2022 | -23.62% | Keybanc | 350 美元 → 315 美元 | 维护 | 超重 |
11/30/2022 | -39.38% | 瑞银(UBS) | → 250 美元 | 启动覆盖开启 | → 中立 |
10/28/2022 | -39.38% | B of A 类证券 | 385 美元 → 250 美元 | 降级 | 买入 → 中性 |
10/28/2022 | -15.13% | Keybanc | 400 美元 → 350 美元 | 维护 | 超重 |
2022 年 7 月 29 日 | -16.35% | Stephens & Co. | 330 美元 → 345 美元 | 维护 | 重量相等 |
2022 年 4 月 29 日 | -0.58% | B of A 类证券 | 475 美元 → 410 美元 | 维护 | 购买 |
2022 年 4 月 29 日 | -3.01% | Keybanc | 475 美元 → 400 美元 | 维护 | 超重 |
2021 年 9 月 15 日 | 24.88% | B of A 类证券 | 450 美元 → 515 美元 | 维护 | 购买 |
07/30/2021 | -3.01% | Stephens & Co. | 360 美元 → 400 美元 | 维护 | 重量相等 |
07/30/2021 | 15.18% | Keybanc | 350 美元 → 475 美元 | 维护 | 超重 |
2021 年 4 月 30 日 | -17.56% | Stephens & Co. | 315 美元 → 340 美元 | 维护 | 重量相等 |
02/19/2021 | -23.62% | Stephens & Co. | 300 美元 → 315 美元 | 维护 | 重量相等 |
11/10/2020 | -15.13% | Keybanc | → 350 美元 | 启动覆盖开启 | → 超重 |
2020 年 10 月 14 日 | -27.26% | Stephens & Co. | → 300 美元 | 启动覆盖开启 | → 重量相等 |
2020 年 4 月 24 日 | — | B of A 类证券 | 升级 | 表现不佳 → 中性 | |
2019 年 12 月 12 日 | — | B of A 类证券 | 降级 | 中性 → 跑赢大盘 | |
07/26/2019 | — | B of A 类证券 | 升级 | 表现不佳 → 中性 | |
05/01/2019 | — | 杰富瑞 | 降级 | 买入 → 持有 | |
04/23/2019 | — | 威廉布莱尔 | 启动覆盖开启 | → 跑赢大盘 |
What is the target price for West Pharmaceutical Servs (WST)?
West Pharmachical Servs(WST)的目标价格是多少?
The latest price target for West Pharmaceutical Servs (NYSE: WST) was reported by Keybanc on August 30, 2023. The analyst firm set a price target for $440.00 expecting WST to rise to within 12 months (a possible 6.69% upside). 12 analyst firms have reported ratings in the last year.
Keybanc于2023年8月30日公布了西部制药服务公司(纽约证券交易所代码:WST)的最新目标股价。该分析公司将目标股价定为440.00美元,预计WST将在12个月内上涨至6.69%(可能上涨6.69%)。去年有12家分析公司公布了评级。
What is the most recent analyst rating for West Pharmaceutical Servs (WST)?
西部药业服务公司(WST)的最新分析师评级是多少?
The latest analyst rating for West Pharmaceutical Servs (NYSE: WST) was provided by Keybanc, and West Pharmaceutical Servs maintained their overweight rating.
West Pharmaceical Servs(纽约证券交易所代码:WST)的最新分析师评级由Keybanc提供,West Pharmaceical Servs维持其增持评级。
When is the next analyst rating going to be posted or updated for West Pharmaceutical Servs (WST)?
West Pharmaceical Servs(WST)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of West Pharmaceutical Servs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for West Pharmaceutical Servs was filed on August 30, 2023 so you should expect the next rating to be made available sometime around August 30, 2024.
分析师在进行了广泛的研究后得出了股票评级,包括阅读公开财务报表、与西部制药服务公司的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应获得4个评级。西部制药服务公司的最后一次评级是在2023年8月30日提交的,因此你应该预计下一个评级将在2024年8月30日左右公布。
Is the Analyst Rating West Pharmaceutical Servs (WST) correct?
分析师对西部制药服务(WST)的评级是否正确?
While ratings are subjective and will change, the latest West Pharmaceutical Servs (WST) rating was a maintained with a price target of $415.00 to $440.00. The current price West Pharmaceutical Servs (WST) is trading at is $412.41, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的西部制药服务公司(WST)评级保持不变,目标股价为415.00美元至440.00美元。西部制药服务公司(WST)目前的交易价格为412.41美元,超出了分析师的预期区间。